Clinical trials in Vila Nova De Gaia – page 44

680 clinical trials in Vila Nova De Gaia, Portugal. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in PortugalEnsaios-Clinicos.pt

Vila Nova De Gaia at a glance

680

clinical trials

Research sites0

Quick filters

680 trials in Vila Nova De Gaia

Open in trial search

HER2 positive breast cancer

Not recruiting

Study on Atezolizumab and Trastuzumab Emtansine for Patients with HER2-Positive Breast Cancer at High Risk of Recurrence After Preoperative Therapy

Registered drug

Study on Atezolizumab and Trastuzumab Emtansine for Patients with HER2-Positive Breast Cancer at High Risk of Recurrence After Preoperative Therapy

Registered drug

Portugal

Participants:18–64 years · 65+ years
Substances:Atezolizumab
Sponsor:F. Hoffmann-La Roche AG

Contact Research Centre

Breast cancer

Not recruiting

Study on Olaparib for Patients with High-Risk HER2-Negative Breast Cancer and BRCA1/2 Mutations After Chemotherapy

Registered drug

Study on Olaparib for Patients with High-Risk HER2-Negative Breast Cancer and BRCA1/2 Mutations After Chemotherapy

Registered drug

Portugal

Participants:18–64 years · 65+ years
Substances:Olaparib
Sponsor:AstraZeneca AB

Contact Research Centre

Chronic kidney disease+1

Not recruiting

Study on Finerenone for Children with Chronic Kidney Disease and Proteinuria Using ACEI or ARB

Investigational

Study on Finerenone for Children with Chronic Kidney Disease and Proteinuria Using ACEI or ARB

Investigational

Portugal

Participants:0–17 years
Substances:Finerenone
Sponsor:Bayer AG

Contact Research Centre

Alopecia areata

Not recruiting

Study on the Safety and Effectiveness of Upadacitinib for Adults and Adolescents with Severe Alopecia Areata

Investigational

Study on the Safety and Effectiveness of Upadacitinib for Adults and Adolescents with Severe Alopecia Areata

Investigational

Portugal

Participants:0–17 years · 18–64 years
Substances:Upadacitinib
Sponsor:AbbVie Deutschland GmbH & Co. KG

Contact Research Centre

Myelofibrosis

Not recruiting

Study of Imetelstat Compared to Drug Combination for Treating Intermediate-2 or High-Risk Myelofibrosis in Patients Not Responding to JAK-Inhibitor Treatment

Registered drugNo placebo

Study of Imetelstat Compared to Drug Combination for Treating Intermediate-2 or High-Risk Myelofibrosis in Patients Not Responding to JAK-Inhibitor Treatment

Registered drugNo placebo

Portugal

Participants:18–64 years · 65+ years
Substances:Alkylating agents
Sponsor:Geron Corp.

Contact Research Centre

Non-small cell lung cancer

Not recruiting

Study of V940 and Pembrolizumab for Patients with Resected Stage II, IIIA, IIIB Non-Small Cell Lung Cancer

Registered drug

Study of V940 and Pembrolizumab for Patients with Resected Stage II, IIIA, IIIB Non-Small Cell Lung Cancer

Registered drug

Portugal

Participants:18–64 years · 65+ years
Substances:MRNA-4157
Sponsor:Merck Sharp & Dohme LLC

Contact Research Centre

Hormone receptor positive breast cancer

Not recruiting

Study of OP-1250 for Treating Advanced or Metastatic ER+, HER2- Breast Cancer in Patients After Endocrine and CDK4/6 Inhibitor Therapy

Registered drugNo placebo

Study of OP-1250 for Treating Advanced or Metastatic ER+, HER2- Breast Cancer in Patients After Endocrine and CDK4/6 Inhibitor Therapy

Registered drugNo placebo

Portugal

Participants:18–64 years · 65+ years
Substances:Anastrozole
Sponsor:Olema Pharmaceuticals Inc.

Contact Research Centre

Essential thrombocythaemia

Not recruiting

Study on Bomedemstat for Patients with Essential Thrombocythemia Not Responding to or Intolerant of Hydroxyurea, Comparing with a Drug Combination

Registered drugNo placebo

Study on Bomedemstat for Patients with Essential Thrombocythemia Not Responding to or Intolerant of Hydroxyurea, Comparing with a Drug Combination

Registered drugNo placebo

Portugal

Participants:18–64 years · 65+ years
Substances:Bomedemstat
Sponsor:Merck Sharp & Dohme LLC

Contact Research Centre

Breast cancer metastatic

Not recruiting

Study comparing giredestrant plus palbociclib versus letrozole plus palbociclib in patients with estrogen receptor-positive, HER2-negative advanced or metastatic breast cancer

Registered drug

Study comparing giredestrant plus palbociclib versus letrozole plus palbociclib in patients with estrogen receptor-positive, HER2-negative advanced or metastatic breast cancer

Registered drug

Portugal

Participants:18–64 years · 65+ years
Substances:Giredestrant
Sponsor:F. Hoffmann-La Roche AG

Contact Research Centre

Bladder transitional cell carcinoma

Not recruiting

Study on TAR-200 and Cetrelimab for Patients with High-Risk Non-Muscle Invasive Bladder Cancer Who Have Not Received BCG Treatment

Registered drugNo placebo

Study on TAR-200 and Cetrelimab for Patients with High-Risk Non-Muscle Invasive Bladder Cancer Who Have Not Received BCG Treatment

Registered drugNo placebo

Portugal

Participants:18–64 years · 65+ years
Substances:Cetrelimab
Sponsor:Janssen Cilag International

Contact Research Centre

Non-small cell lung cancer+1

Not recruiting

Study Comparing Pralsetinib and Standard Drug Combination for Patients with Advanced RET Fusion-Positive Non-Small Cell Lung Cancer

Registered drugNo placebo

Study Comparing Pralsetinib and Standard Drug Combination for Patients with Advanced RET Fusion-Positive Non-Small Cell Lung Cancer

Registered drugNo placebo

Portugal

Participants:18–64 years · 65+ years
Substances:Carboplatin
Sponsor:F. Hoffmann-La Roche AG

Contact Research Centre

Diffuse large B-cell lymphoma

Not recruiting

Study on the Safety and Effectiveness of Epcoritamab with R-CHOP for Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)

Registered drugNo placebo

Study on the Safety and Effectiveness of Epcoritamab with R-CHOP for Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)

Registered drugNo placebo

Portugal

Participants:18–64 years · 65+ years
Substances:Cyclophosphamide
Sponsor:AbbVie Deutschland GmbH & Co. KG

Contact Research Centre

Other cities in Portugal

The busiest research cities in the country

All 47 cities in Portugal

Clinical research in Vila Nova De Gaia

What the registry says about research in the country

01 Oncology Research

Innovative clinical trials focusing on head and neck cancer, breast cancer, and multiple myeloma treatments. Studies include evaluations of novel therapies for both early-stage and metastatic conditions.

Advanced Head & Neck Squamous Cell Carcinoma
HER2-positive Breast Cancer
Multiple Myeloma Maintenance Therapy

Research encompasses targeted therapies and combination treatments aimed at improving patient outcomes.

02 Autoimmune Disorders

Comprehensive studies investigating treatments for various autoimmune conditions, including Sjögren's Syndrome and systemic sclerosis. Focus on developing targeted therapies for immune system regulation.

Primary Sjögren's Disease
Diffuse Cutaneous Systemic Sclerosis
Immune Thrombocytopenia

Evaluating novel biological therapies to address complex autoimmune manifestations.

03 Metabolic & Cardiovascular Studies

Research focused on obesity management and cardiovascular health. Studies evaluate new therapeutic approaches for weight management and cardiovascular disease prevention.

Obesity Treatment
Pulmonary Arterial Hypertension
Cardiovascular Risk Management

Investigating innovative treatments to address growing metabolic health challenges.

Back to Portugal All countries